CD274 and neoplasm: In addition to using PD-L1 expression as a biomarker for ICI therapy responsiveness, other biomarkers such as tumor mutational burden (TMB), DNA damage response (DDR) gene defects, and microsatellite instability (MSI) are being studied as markers to predict susceptibility to ICI therapy.